Rattibha

EnvisionRheumat

12 Tweets 18 reads Jun 02, 2022

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
🔹Disease activity pathway to control damage/death
🔹Still a major cause of death in young women
🔹We haven't been able to solve the mortality mystery yet

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
Failure to reach LLDAS
Higher GC leads
⬆️ Mortality

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
🔹Type 1 interferon and B-Cell/BLyS signature 2 faces of SLE pathogenesis
🔹Type 1 interferon Response is dysregulated in SLE

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
🔹 SLE pts at high risk of poor outcomes with COVID
🔹 ⬆️ disease activity and MMF/RTX asso. with poor outcomes
🔹At least 9 B-cell/ml req for vaccine response

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
🔹Anti-INF ab in SLE and COVID
🔹Bimodal Interferon Signature in Lupus

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
🔹Treatment for Extra-Renal Recommendation
🔹 Remission and LDA definition

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
Who responds to Belimumab
⬆️ disease activity 👉🏻 SLEDAI>10
⬆️dsDNA levels
⬇️C3,C4
requiring GC> 10mg/day

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
🔹 In Patients with high interferon Signature 👉🏻 Aniflrolumab works but not in Low INF signature

#EULAR2022
WIN Session
From pathogenesis to new therapies: what is new in SLE?
🔹 where Blys inhibition and where INF inhibition would be interesting to know
🔹 Recent Negative trials with JAKi and BAFFi/RTX
🔹BDCA a new attractive target - specially in arthritis